Paradigm shift in CTD PAH -Early triple therapy in patients with intermediate and high risk -Sotatercept, a blocker of activin-Smad2/3 signaling have increased survival importantly Data presented by Dr Khanna @RheumNow #APLAR25 https://t.co/Z4yA6DwtOb